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To examine whether elevated antinuclear antibody (ANA) titers reported in random human population
of arsenic contaminated villages can be reverted to the normal range by administration of a potentized
homeopathic drug, Arsenicum album, randomly selected volunteers in two arsenic contaminated villages
and one arsenic-free village in West Bengal (India) were periodically tested for their ANA titer as well as
various blood parameters in two types of experiments: ‘placebo-controlled double blind’ experiment for
shorter duration and ‘uncontrolled verum fed experiment’ for longer duration. Positive modulation of
ANA titer was observed along with changes in certain relevant hematological parameters, namely total
count of red blood cells and white blood cells, packed cell volume, hemoglobin content, erythrocyte
sedimentation rate and blood sugar level, mostly within 2 months of drug administration. Thus, Arsen-
icum album appears to have great potential for ameliorating arsenic induced elevated ANA titer and
other hematological toxicities.
Keywords: antinuclear antibody (ANA) – Arsenicum album – arsenic toxicity – blood cells – blood
sugar – ESR – human – homeopathic remedy
Introduction
Contamination of drinking groundwater with various toxic
metal compounds including arsenic has become a menacing
problem in many countries. It has affected millions of people
globally distributed over some 20 countries, including over
100 million people in West Bengal (India) and Bangladesh
alone (1). Prolonged exposure to Arsenic (‘As’) leads to vari-
ous ailments and dysfunctions of several vital organs such as
liver, kidney and lung apart from its toxic effects manifested
on skin and other epidermal tissue (2). Most of the affected
people in general complain of muscle and joint pains and are
highly depressed with various gastric problems and general
weakness. Many people look pale and anemic and seem
resigned to fate. Various disease symptoms and diseases invol-
ving different organs have been reported in people of arsenic
affected areas (3–5). However, no systematic survey on incid-
ence of any systemic autoimmune disorder occurring in ran-
dom populations of arsenic contaminated villages seems to
have been carried out so far although some sporadic case stud-
ies have been reported (6–7). However, in one of our recent
surveys, we observed an alarming prevalence of ANA-
positive subjects in two arsenic contaminated villages of
West Bengal (8). Moreover, efforts to reverse or alter ANA
titer through administration of any orthodox medicine often
bringing adverse side-effects, even though the treatment with
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ing of patients with rheumatoid arthritis or other systemic dis-
orders such as systemic lupus erythematosus (9). Therefore,
the present study was undertaken to examine whether a potent-
ized homeopathic remedy, Arsenicum album, reported to have
the ability to ameliorate arsenic toxicity in both mice (10–18)
and human subjects (19), could revert the alarmingly
high incidence of elevated ANA titers observed in random
populations of high-risk arsenic contaminated villages in
West Bengal (8) without any adverse ill-effects. Our effort to
eliminate arsenic from blood and urine through administration
of a potentized homeopathic drug, Arsenicum album-30,
proved quite successful as revealed from the mobilization of
arsenic content from blood and urine and also from positive
modulation in activities of several toxicity biomarkers such
as acid phosphatases (AcP) and alkaline phosphatases
(AlkP), alanine amino transferase (ALT) and aspartate amino
transferase (AST), lipid peroxidase (LPO) and reduced gluta-
thione (GSH) in human subjects (19). We were encouraged
to examine whether this remedy, Arsenicum album, in two dif-
ferent potencies, namely Arsenicum album-30 and Arsenicum
album-200, could also make positive alteration or reversal of
ANA-positive titer back to normal in different groups of
people studied in these two high-risk arsenic contaminated
villages. Further, we examined whether there was any positive
modulation in the total count (TC) of red blood cells(RBCs)
and white blood cells (WBCs), packed cell volume (PCV),
hemoglobin content and level of blood sugar in these subjects
after administration of the homeopathic remedy, because
anemia, diabetes etc are often associated with various systemic
autoimmune disorders (9).
Methods
Selection of Work Site
The village Ghetugachhi (under Chakdaha Block, District
Nadia, West Bengal) is one of the worst affected and earliest
known (since 1995) arsenic contaminated villages in West
Bengal. Dakshin Panchpota situated  8 km away under the
same block and district is another village where arsenic has
been detected in tube well waters only since 2002.
Arsenic-free water plants have been installed only since
November 2002 and December 2004, respectively, in these
two villages. The villagers mainly use water from the plant
for drinking, but generally use other water sources for cooking
and other purposes. Thus, the people of Ghetugachhi were
known to be subjected to arsenic exposure for a greater length
of time since detection than those of the Dakshin Panchpota
village. The general symptoms of extreme fatigue, rheumatic
joint and muscle pains, and gastric and urinary problems
were quite prevalent in villagers of these two arsenic contam-
inated villages. A few people also had scleroderma and various
other skin diseases. Mainly because of its proximity to the
laboratory (within 30–40 km), and the availability of the
arsenic-free water to the villagers, these two villages were
selected as the site of our work.
Another village, Padumbasan, under Tamluk Sub-Division
of Purba Medinipur district,  160 km away from these two
villages, reported to be free of groundwater arsenic (also con-
firmed by us by testing water samples collected from several
tube wells in that village), was selected for scoring blood
data which could serve as negative controls. Most of the volun-
teers had generally good health, albeit with minor gastric prob-
lem, but two of them complained of occasional muscle and
joint pains, including one who was diagnosed with arthritis.
The Subjects
Our objectives and mission of testing the efficacy of a potent-
ized homeopathic remedy that worked well in mice in our earl-
ier studies were explained to the villagers at an awareness
program on different aspects of large-scale arsenic contamina-
tion in several villages. Active help and cooperation were
sought from these villagers to undertake this human trial.
Initially the villagers did not enthusiastically volunteer. Most
of them appeared to be reluctant presumably because (i)
many of them simply did not believe in homeopathy; (ii)
many had taboo against giving blood which, they believed,
would cause them further harm; and (iii) some researchers
had earlier taken blood, urine, nail and hair samples from
them promising them to give effective remedies, but never
came back again with either the results or the promised rem-
edy! after great perseverance, however, some villagers agreed
to undertake a blind placebo-controlled study only for 1
month, but most others maintained that they would agree to
sign the ‘informed consent’ form and give us their blood sam-
ples only if they were assured that they would be given the
actual drug for a long time and not any ‘placebo’. Many of
the latter group of people were indeed very sick, some with
visible symptoms of arsenicosis, some with serious gastric
and other problems including liver and lung ailments, and a
few others with bad skin lesions. Further, since there are no
hospitals or clinics to care for any emergency situation, the
study had to be performed under obvious limitations and was
designed accordingly in the following manner.
Controlled Experiments
A group of 26 volunteers (of the same socioeconomic group
as that of the village Dakshin Panchpota in district Nadia)
were chosen on a random basis (as far as practicable from
the willing villagers, that is!) from the village Padumbasan in
Purba Medinipur district to provide data which could serve
as negative control (Group I).
A group of 43 volunteers were selected from Dakshin
Panchpota (Group II), who agreed to undertake double blind
placebo trial (that is, each of them was allowed to choose a
vial from a medicine tray containing equal number of numeric-
ally marked vials of either ‘placebo’ or ‘verum’, prepared by
the associated homeopathy doctor, who was not a member of
the team entrusted to observation. The content of the vials
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doctor who prepared them, and was not known before either
by any of the observers entrusted to take care of the different
parameters of the study or to the subjects who selected their
own vial; however, it transpired later that the ‘placebo’ and
‘verum’ vials were not randomly placed in the tray, which
possibly should have been done, but kept merely in different
rows by the associated homeopathy doctor. This limited the
actual randomization process, as some volunteers simply
picked up consecutive vials one after the other from the same
row) only for 1 month. All the parameters of study as listed
below were studied in these two groups.
The male volunteers as well as unmarried women volunteers
were permanent residents of the three villages since birth, but
the womenfolk married to the villagers became residents
only after their marriage.
Uncontrolled ‘Verum’ Fed Experiments
Since volunteers did not agree to subject themselves to
‘placebo’ trial, but were only eager to take the ‘verum’ on their
own, the next group (Group III) of 83 volunteers from Dakshin
Panchpota village received only Arsenicum album-30 and
their blood was drawn after 2 months of drug administration
for studying the various blood parameters except for erythro-
cyte sedimentation rate (ESR) and PCV.
As the inhabitants of Ghetugachhi had been exposed to
groundwater arsenic for a longer period than those of Dakshin
Panchpota, 47 volunteers (Group IV) from this village were
administered Arsenicum album-200, a higher potency, which
is claimed in homeopathic doctrine to have better efficacy in
case of chronic diseases (or long-standing disorders). This
was performed also for the purpose of examining relative effi-
cacy after 2 months of administration of Arsenicum album-200
and Arsenicum album-30 in two groups of arsenic intoxicated
subjects. All parameters were studied in them except for PCV
and ESR.
Administration of ‘Verum’ and ‘Placebo’
The potentized homeopathic drugs, Arsenicum album-30
and Arsenicum album-200 (verum) and potentized ethyl
alcohol (‘placebo’, i.e. succussed ethyl alcohol-30 and ethyl
alcohol-200) used in this study were prepared by Boiron
Laboratory, Lyon, France following the homeopathic proced-
ure of dilution and succussion. Sugar globules (No.20) were
soaked with either verum or placebo and were given to
subjects, 8 globules forming a dose, twice daily for 10 days
for Arsenicum album-30 and then withdrawn for 10 days,
and then given for 10 days again, and so on. However,
Arsenicum album-200 was given as a single dose everyday
for 5 consecutive days and withdrawn for 20 days to repeat




Volunteers of different age-groups and sex were told not to
take any food before drawing blood in the morning.
Blood was drawn from their superficial vein around the fore-
arm region by the routine procedure using sterile disposable
syringe and needle. Blood was collected in two vials: one
containing EDTA (anti-coagulant) and the other without
EDTA and brought to the laboratory in flasks containing ice.
In the laboratory, blood was centrifuged at 8000 g for 10 min
and serum was obtained from blood without EDTA, which
was used for ANA test. Blood with EDTA was also used
for determination of ESR, PCV, Hb, and TC of RBC and
WBC. Plasma was isolated from blood with EDTA by centri-
fugation at 8000 g for 10 min for the determination of blood
sugar level.
ANA and Scl-70 Tests
A small part of blood serum was taken for ANA test by using
an ANA Detect kit (ANA ORG 600; ORGENTEC Diagnostika
GmbH, Germany) with the aid of an ELISA Reader (ELDEX
3.8, USA). This assay collectively detects, in one well,
ANAs against some 20 antigens, including double-stranded
DNA (ds-DNA, nDNA), histones, SS-A/Ro, SS-B/La, Sm,
SmRNP, Scl-70, PM-Scl-100, Jo-1, and centromeric antigens.
As ELISA test gives a better and dependable result for detec-
tion of ANA titer, this method was preferred. Blood sera of
the ANA-positive subjects were also subjected to the Scl-70
antibody test by the specific anti-Scl-70 antibody kit also
obtained from Germany (ANA ORG 600; ORGENTEC Dia-
gnostika GmbH).
Other Blood Parameters
Blood with EDTA was used in a hemocytometer for TC of
RBC and WBC by the routine method (improved Neubauer
Hemocytometer method).
PCV was determined by the standard Wintrobe method.
For determination of ESR, the standard Westergren method
was followed.
For blood sugar determination, standard glucose test kit
(enzymatic, GOD-POD method) obtained from Span Dia-
gnostics Limited, India, was used and the level of blood sugar
was determined by a Spectrophotometer (Pharmaspec, UV
1700, Shimadzu, Japan) at 550 nm.
Hemoglobin content was determined by Sahli’s method with
the help of a hemometer (Marienfield, Germany).
Determination of As Content in Water
Arsenic content of water was determined by the standard
procedure of Atomic Absorption Spectroscopy using Perkin-
Elmer Analyst AA200, USA (8).
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Levels of significance between data of two fixation intervals in
either placebo fed or drug fed series were analyzed by per-
formingstudent’s ‘t’-test. The differences between data of sub-
jects before feeding of drug were compared with that of data
after feeding of drug for different time intervals. Further, the
data of subjects living in arsenic contaminated villages were
also compared with that of arsenic-free village (negative con-
trol) before administration of drug, in order to show whether
the differences were statistically significant or not at the time
of starting the experiments.
Results
As Content in Water Collected from Different
Tube Wells
The ‘As’ content of water from three tube wells of Padum-
basan village tested was found to be below the detectable limit.
However, although the ‘As’ content of water collected from
the arsenic-free plants of both Ghetugachhi and Dakshin
Panchpota tested ‘As’ content below 10 ppb (within the per-
missible range of up to 50 ppb for third world countries) on
an average of three tests performed on three different days,
some other tube wells in both the villages had water samples
measuring an ‘As’ content between 65.9 and 330.37 ppb in
Ghetugachhi (10 tube wells tested) and between 94.35 and
339.38 ppb in Dakshin Panchpota village (5 tube wells tested),
which are well above the recommended safe level.
ANA Titer
Out of 26 controls (negative) of Group I living in Padumbasan
village (arsenic-free), only one woman having symptoms of
arthritis tested ANA positive while all others tested negative
(see Table 1).
The Group II controlled study for 1 month (Table 2) did not
reveal any clear-cut results. There was some indication of pos-
itive alteration of titer toward negativity in the drug fed sub-
group. Interestingly, in the placebo fed ones, there was also a
slight decrease in the level although the change was not so
remarkable.
However, in the uncontrolled Group III receiving Arsenicum
album-30 for 2 months, all ANA-positive subjects tested negat-
ive. In this group, out of a total of 83 subjects (50 males and
33females),10malesand6femaleswereANApositive,6males
and 2 females wereonthe borderlineofpositivity, whilethe rest
tested negative, before administration of the remedy.
Similarly, in the other uncontrolled Group IV subjects living
at Ghetugachhi village, all of the ANA-positive cases tested
negative for ANA titer after 2 months of administration of
the remedy, Arsenicum album-200. In this group, out of 47
volunteers (33 male and 14 female), as many as 27 males
and 13 females tested positive while ANA titer of 3 males
and 1 female were in the borderline of positivity before admin-
istration of Arsenicum album-200.
Scl-70 Titer
Out of a total of 56 ANA-positive cases examined, only one
subject was found to be Scl-70 positive.
Table 1. Classified data on expression of ANA in relation to age and sex
Age group Name of villages
Padumbasan Ghetugachhi Dashin Panchpota
Male Female Male Female Male Female
þve B  ve þve B  ve þve B  ve þve B  ve þve B  ve þve B  ve
<20 years 0 0 0 0 0 0 9 1 1 3 1 0 2 0 9 0 0 3
20–40 years 0 0 18 1 0 0 13 1 2 7 0 0 4 4 14 2 1 12
>40 years 0 0 5 0 0 2 5 1 0 3 0 0 4 1 12 4 1 10
Total populations studied (156): Padumbasan, 26 (Male 23, Female 3); Ghetugachhi, 47 (Male 33, Female 14); and Dakshin Panchpota, 83 (Male 50, Female 33).
B ¼ borderline.
Table 2. Reversal of expression of ANA in Group II populations from the village Dakshin Panchpota
Age group Placebo Drug (Ars alb-30)
BP AP 1M BD AD 1M
Male Female Male Female Male Female Male Female
þve B  ve þve B  ve þve B  ve þve B  ve þve B  ve þve B  ve þve B  ve þve B  ve
<20 years 1 0 12 0 0 1 1 0 12 0 0 1 0 1 3 2 0 4 0 0 4 1 NA1 0 4
20–40 years 2 0 1 0 0 0 2 0 1 0 0 0 1 0 2 4 3 3 0 0 3 0 0 10
>40 years 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 1 1 0 0 1
Total populations studied, 43: Placebo fed, 17 (Male 16, Female 1); Drug (Ars alb-30) fed, 26 (Male 9, Female 17); NA ¼ blood not available (dropped out),
BP ¼ before administration of placebo; AP ¼ after administration of placebo; BD ¼ before administration of the drug; AD ¼ after administration of the drug,
1M ¼ one month.
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TC of RBC
The mean total counts of RBC and WBC in males and females
have been provided in the histograms (Fig. 1a–f).
A critical analysis of data in the controlled study (Group II)
reveals that there was an elevation of TC of RBC (Fig. 1a) a lit-
tle more than that of the placebo fed series after 1 month. For
comparison, the data of the negative control (Group I) have
also been presented.
In the uncontrolled verum fed Group III, the elevation was
much more pronounced after 2 months of administration of
Arsenicum album-30 in TC of RBC (Fig. 1b).
The same trend as noticed in Arsenicum album-30 fed series
could also be followed in the other uncontrolled verum Ars
alb-200 fed Group IV, where there was also a very distinct
elevation (Fig. 1c). The females showed a little better response
as compared with males in this group.
TC of WBC
In the controlled Group II, the single female in the placebo
fed subgroup tended to show WBC more than their male
counterparts and the number was even elevated after
1 month (Fig. 1d). But in the drug fed subgroup, apparently
the increase of WBC count was greater in females than
males.
In the uncontrolled Group III verum fed subjects, there was
also a clear increase in the number of WBC after 2 months of







Figure 1. (a) Histogram showing changes in TC of RBC in placebo fed and
drug fed groups of 1 month treatment (Ars alb-30); statistical significance
levels were calculated by considering differences between data of subjects of
Group I and subjects of Group II, before administration of either placebo
(BP) or verum (BD-30); only significant differences have been shown:
aP < 0.05;
bP < 0.01;
cP < 0.001. (AP = after administration of placebo;
AD-30 = after administration of Ars alb-30). (b) Histogram showing changes
in TC of RBC in drug fed groups of 2 month treatment (Ars alb-30); statistical
significance levels were calculated by considering differences between Group
I and Group III before drug administration (Ars alb-30) and within Group III
before and after administration of the drug. (c) Histogram showing changes
in TC of RBC of 2 month treatment (Ars alb-200); statistical significance
levels were calculated between Group I and Group IV before administration
of the drug and within Group IV before and after administration of the drug
(Ars alb-200). (d) Histogram showing changes in TC of WBC in placebo fed
and drug fed groups (Ars alb-30) of 1 month treatment; statistical significance
levels were calculated by considering differences between data of subjects of
Group I and subjects of Group II, before administration of either placebo
(BP) or verum (BD-30). (e) Histogram showing changes in TC of WBC in
drug fed groups (Ars alb-30) of 2 month treatment; statistical significance
levels were calculated by considering differences between Group I and Group
III before drug administration (Ars alb-30) and within Group III before and
after administration of the drug. (f) Histogram showing changes in TC of
WBC in drug fed groups of 2 month treatment (Ars alb-200) against negative
control; statistical significance levels calculated between Group I and Group
IV before administration of the drug and within Group IV before and after
administration of the drug (Ars alb-200).
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Arsenicum album-200, there was a little fall in TC of WBC
after 2 months (Fig. 1f).
PCV
The PCV in both males and females was on the lower side in
the controlled group (Group II); there was only a marginal
rise in the placebo subgroup. However, in the verum fed sub-
group, there was a fairly clear increase in data of females,
but the PCV in males actually decreased slightly after 1 month
(Fig. 2).
ESR
The ESR level in verum fed subgroup in the controlled Group
II series decreased appreciably in both males and females,
slightly more in females, after 1 month of taking the remedy
(Fig. 3). However, interestingly, there was very little decrease
observed in the placebo fed subgroup.
Blood Sugar
In the controlled Group II, fasting blood sugar level in both the
placebo fed and drug fed subgroups were initially somewhat
low, and in both cases there was some elevation after taking
placebo or drug for 1 month (Fig. 4a).
The base level of fasting blood sugar observed in the uncon-
trolled Group III before administration of the remedy was quite
high at 215.72, which was found to be decreased appreciably
to the normal level after 2 months of drug administration
(Fig. 4b).
On the other hand, in the Arsenicum album-200 fed Group
IV, the fasting blood sugar level was actually slightly elevated
after 2 months of drug administration (Fig. 4c).
Hemoglobin
In the controlled Group II, the hemoglobin content was
elevated in both the placebo fed and verum fed subgroups
(Fig. 5a), in both males and females.
Figure 2. Histogram showing changes in PCV of subjects fed either placebo
or drug (Ars alb-30) of 1 month treatment group against negative control;
statistical significance levels calculated by considering differences between
data of subjects of Group I and subjects of Group II, before administration of




Figure 3. Histogram showing changes in ESR of subjects fed either placebo
or drug (Ars alb-30) of 1 month treatment group against negative control;
statistical significance levels were calculated by considering differences
between data of subjects of Group I and Group II, and within Group II before







Figure 4. (a) Histogram showing changes in blood sugar level of subjects
fed either placebo or drug (Ars alb-30) of 1 month treatment, statistical signi-
ficance levels were calculated by considering differences between data of
subjects of Group I and Group II, and within Group II before and after admin-
istration of either placebo (BP) or verum (BD-30);
aP < 0.05;
bP < 0.01;
cP < 0.001. (b) Histogram showing changes in blood sugar level of subjects
fed drug (Ars alb-30) for 2 months; statistical significance levels were calcu-
lated by considering differences between Group I and Group III before drug
administration and within Group III before and after administration of the
drug (Ars alb-30). (c) Histogram showing changes in blood sugar level of sub-
jects fed drug (Ars alb-200) for 2 months against negative control; statistical
significance levels were calculated between Group I and Group IV before
administration of the drug and within Group IV before and after administration
of the drug (Ars alb-200).
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the base data before drug administration, but the level was
found to be slightly elevated after 2 months (Fig. 5b).
However, there was also a little elevation in the level of
hemoglobin in Group IV (Fig. 5c) as well, but not as much
as in Group III (Fig. 5b), in both males and females.
Discussion
Systemic autoimmune diseases are usually due to defects in
immune regulation that results in hyperactive T and B cells.
This kind of disease is best exemplified by antinuclear
antibodies in systemic lupus erythematosus where patholog-
ical changes are widespread, similar to the symptoms
observed in subjects exposed to chronic groundwater arsenic
contamination. Autoimmune disorders are also known to cause
defective red cell maturation (9), leading to diseases such as
pernicious anemia and hemolytic anemia. Autoimmune anti-
bodies are also reported to cause decline in platelet counts.
The baseline data obtained for various blood parameters
indicated that, presumably because of not receiving nutritious
food, most of the subjects were showing some signs of low
blood count, low hemoglobin content, high level of ESR etc,
which possibly made them more vulnerable to the additional
effects of chronic exposure to arsenic through groundwater
contamination. Long exposure to this chronic poison may be
the main reason behind their testing ANA positive (8). It was
quite amazing that the administration of the two potencies of
Arsenicum album successfully reverted their ANA titers to
the normal range.
Further, data also revealed that there was indeed a positive
modulation of some other blood parameters which may be
either contributing as a cause or effect toward the conversion
of ANA titer from positivity to negativity.
Autoimmunity can affect any part of the body and cause
organ specific diseases such as Hashimoto’s disease, or else
may cause non-organ specific diseases, which are often called
systemic autoimmune diseases (9,20,21). In systemic autoim-
mune diseases, the immune responses are directed toward a
broad range of target antigens and involve a number of organs
and tissues.
Chronic autoimmune reactions are now thought most
likely to play a key role in the progressive destruction of
the insulin producing B cells in the islets of Langerhans
(22,23). However, a high blood sugar level in many subjects
of Group III living in Dakshin Panchpota village was
encountered while the same in others appeared to be more or
less normal. It was, however, not known whether the elevated
blood sugar was due to destruction of the insulin producing
cells or not.
In SLE pathological changes are seen in the skin, such as
rash on face, in kidney glomeruli, joints, serous membranes
and blood vessels, similar to the symptoms seen in arsenic
intoxicated subjects.
Incidentally, ideal goal for treatment of autoimmune dis-
eases is considered to be the removal of the causative factors
for the autoimmune responses. The recent therapies for
autoimmune diseases are more of palliative nature than being
capable of providing a permanent cure (9). Therefore, the
major strategy of the treatment is generally aimed at suppress-
ing the immune system. Corticosteroids are often used for this
purpose to suppress inflammatory lesions and to prolong the
life of patients. However, general immunosuppression is rather
undesirable as it puts the patient at greater risk for infection or
development of cancer (9,22). But homeopathic therapy is
devoid of this danger because of its efficacy in ultra-low doses
and its non-toxic nature (24).
ANAs are reported to be present in lower titers in several dis-
orders that include liver diseases, leprosy, multiple sclerosis,
juvenile rheumatoid arthritis, etc. (25,26). It was not precisely




Figure 5. (a) Histogram showing changes in hemoglobin content of subjects
fed either placebo or drug (Ars alb-30) of 1 month treatment against negative
control; statistical significance levels calculated by considering differences
between data of subjects of Group I and Group II, and within Group II before
and after administration of either placebo (BP) or verum (BD-30);
aP < 0.05;
bP < 0.01;
cP < 0.001. (b) Histogram showing changes in hemoglobin con-
tent of subjects fed drug (Ars alb-30) for 2 months against negative control;
statistical significance levels were calculated by considering differences
between Group I and Group III before drug administration and within
Group III before and after administration of the drug (Ars alb-30). (c) Histo-
gram showing changes in hemoglobin content of subjects fed drug (Ars
alb-200) for 2 months; statistical significance levels were calculated between
Group I and Group IV before administration of the drug and within Group
IV before and after administration of the drug (Ars alb-200).
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the elevated ANA titer found in many of them.
The Ghetugachhi population had an alarmingly high
frequency of occurrence of ANA in their blood sera. Out of
47 subjects, 40 (85.1%) tested positive and 4 others were on
the borderline (Table 1). In Dakshin Panchpota , a total of
16 persons (19.2%) out of 83 tested positive while 7 were
in the threshold. This would possibly indicate a direct
relationship of exposure-time to the development of such
autoimmune disorder, as subjects of both the villages are
more or less from the same economic background and
mostly live on undernourished diet. But the development of
autoimmune disorder in such a large scale, irrespective of
being a cause or consequence of arsenic toxicity, may be
attributable to the development of various other fatal diseases,
which may ultimately become the cause for the large-scale
premature mortality encountered in these villages. People of
almost all age-groups were found to be more vulnerable;
females were a little more vulnerable than males (8). Incident-
ally, in normal random populations, the incidence of ANA-
positive cases is reported to be about 5%, as also found in the
random survey of Padumbasan population. Generally, ANA-
positive cases are much higher in females (9 female: 1 male),
particularly in women during their child-bearing years.
Interestingly, quite a few villagers in both villages did not
apparently show symptoms of inflammatory rheumatic
diseases, yet they tested ANA positive, indicating its possible
use in early prognosis for arsenic intoxication. Therefore, sim-
ilar studies by other researchers are highly warranted and
encouraged, because verification and confirmation of results
could bring hope to the millions of arsenic victims and possible
sufferers by way of providing an easy and affordable means, at
least to lessen if not get rid of their immense suffering from
groundwater arsenic contamination.
How the ultra-low doses of the homeopathic remedy could
bring about such hematological and immunological changes
remain unclear. But one hypothesis to explain such changes
could be that signals carried by potentized homeopathic drugs
might be able to trigger a cascade action of relevant genes (24)
back to their normal functioning.
In view of only one subject being Scl-70 positive, further
studies with other more specific antibodies such as ds-DNA,
anti-centromeric antibodies, ENA etc. are needed to be con-
ducted in future to pinpoint the exact nature of the antigen(s)
being targeted by chronic arsenic intoxication.
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